Phil John Borman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Phil John Borman has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Marion J. Chatfield
GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
6 shared publicationsAdam Looker
Vertex Pharmaceuticals Inc
3 shared publicationsBatool Ahmed Omer
GlaxoSmithKline Ltd
3 shared publicationsIvana Damjanov
Product Development and Statistical Sciences, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK
3 shared publicationsJeffrey M. Kallemeyn
AbbVie Inc
3 shared publications- Matt Popkin
GlaxoSmithKline Ltd
3 shared publications
Latest Publications
- Open Access
- 8 January 2024
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (3) , 966-979
Ongoing Analytical Procedure Performance Verification Using a Risk-Based Approach to Determine Performance Monitoring Requirements
The analytical procedure life cycle (APLC) provides a holistic framework to ensure analytical procedure fitness for purpose. USP's general chapter considers the validation activities that take place across the entire analytical procedure lifecycle and provides a three-stage framework for its implementation. Performing ongoing analytical procedure performance verification (OPPV) (stage 3) ensures that the procedure remains in a state of control across its lifecycle of use post validation (qualification) and involves an ongoing program to collect and analyze data that relate to the performance of the procedure. Knowledge generated during stages 1 (procedure design) and 2 (procedure performance qualification) is used as the basis for the design of the routine monitoring plan to support performance verification (stage 3). The extent of the routine monitoring required should be defined based on risk assessment, considering the complexity of the procedure, its intended purpose, and knowledge about process/procedure variability. The analytical target profile (ATP) can be used to provide or guide the establishment of acceptance criteria used to verify the procedure performance during routine use (e.g., through a system/sample suitability test (SST) or verification criteria applicable to procedure changes or transfers). An ATP however is not essentially required to perform OPPV, and a procedure performance monitoring program can be implemented even if the full APLC framework has not been applied. In these situations, verification criteria can be derived from existing validation or system suitability criteria. Elements of the life cycle approach can also be applied retrospectively if deemed useful.
- 8 January 2024
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (3) , 966-979
Open AccessOngoing Analytical Procedure Performance Verification Using a Risk-Based Approach to Determine Performance Monitoring Requirements
The analytical procedure life cycle (APLC) provides a holistic framework to ensure analytical procedure fitness for purpose. USP's general chapter considers the validation activities that take place across the entire analytical procedure lifecycle and provides a three-stage framework for its implementation. Performing ongoing analytical procedure performance verification (OPPV) (stage 3) ensures that the procedure remains in a state of control across its lifecycle of use post validation (qualification) and involves an ongoing program to collect and analyze data that relate to the performance of the procedure. Knowledge generated during stages 1 (procedure design) and 2 (procedure performance qualification) is used as the basis for the design of the routine monitoring plan to support performance verification (stage 3). The extent of the routine monitoring required should be defined based on risk assessment, considering the complexity of the procedure, its intended purpose, and knowledge about process/procedure variability. The analytical target profile (ATP) can be used to provide or guide the establishment of acceptance criteria used to verify the procedure performance during routine use (e.g., through a system/sample suitability test (SST) or verification criteria applicable to procedure changes or transfers). An ATP however is not essentially required to perform OPPV, and a procedure performance monitoring program can be implemented even if the full APLC framework has not been applied. In these situations, verification criteria can be derived from existing validation or system suitability criteria. Elements of the life cycle approach can also be applied retrospectively if deemed useful.
- 14 July 2023
- Published by Springer Nature
- p. 199-219
Analytical Target Profile (ATP) and Method Operable Design Region (MODR)
- 14 July 2023
- Published by Springer Nature
- p. 199-219
Analytical Target Profile (ATP) and Method Operable Design Region (MODR)
- 9 March 2022
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 26 (4) , 1029-1037
Regulatory Highlights
- 9 March 2022
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 26 (4) , 1029-1037
Regulatory Highlights
- Open Access
- 20 December 2021
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 94 (2) , 559-570
Selection of Analytical Technology and Development of Analytical Procedures Using the Analytical Target Profile
A structured approach to method development can help to ensure an analytical procedure is robust across the lifecycle of its use. The analytical target profile (ATP), which describes the required quality of the reportable value to be produced by the analytical procedure, enables the analytical scientist to select the best analytical technology on which to develop their procedure(s). Once the technology has been identified, screening of potentially fit for purpose analytical procedures should take place. Analytical procedures that have been demonstrated to meet the ATP should be evaluated against business drivers (e.g., operational constraints) to determine the most suitable analytical procedure. Three case studies are covered from across small molecules, vaccines, and biotherapeutics. The case studies cover different aspects of the analytical procedure selection process, such as the use of platform method development processes and procedures, the development of multiattribute analytical procedures, and the use of analytical technologies to provide product characterization knowledge in order to define or redefine the ATP. Challenges associated with method selection are discussed such as where existing pharmacopoeial monographs link acceptance criteria to specific types of analytical technology.
- 20 December 2021
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 94 (2) , 559-570
Open AccessSelection of Analytical Technology and Development of Analytical Procedures Using the Analytical Target Profile
A structured approach to method development can help to ensure an analytical procedure is robust across the lifecycle of its use. The analytical target profile (ATP), which describes the required quality of the reportable value to be produced by the analytical procedure, enables the analytical scientist to select the best analytical technology on which to develop their procedure(s). Once the technology has been identified, screening of potentially fit for purpose analytical procedures should take place. Analytical procedures that have been demonstrated to meet the ATP should be evaluated against business drivers (e.g., operational constraints) to determine the most suitable analytical procedure. Three case studies are covered from across small molecules, vaccines, and biotherapeutics. The case studies cover different aspects of the analytical procedure selection process, such as the use of platform method development processes and procedures, the development of multiattribute analytical procedures, and the use of analytical technologies to provide product characterization knowledge in order to define or redefine the ATP. Challenges associated with method selection are discussed such as where existing pharmacopoeial monographs link acceptance criteria to specific types of analytical technology.
- Open Access
- 12 February 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (2) , 150
Development and Validation of an in-line API Quantification Method Using AQbD Principles Based on UV-Vis Spectroscopy to Monitor and Optimise Continuous Hot Melt Extrusion Process
A key principle of developing a new medicine is that quality should be built in, with a thorough understanding of the product and the manufacturing process supported by appropriate process controls. Quality by design principles that have been established for the development of drug products/substances can equally be applied to the development of analytical procedures. This paper presents the development and validation of a quantitative method to predict the concentration of piroxicam in Kollidon® VA 64 during hot melt extrusion using analytical quality by design principles. An analytical target profile was established for the piroxicam content and a novel in-line analytical procedure was developed using predictive models based on UV-Vis absorbance spectra collected during hot melt extrusion. Risks that impact the ability of the analytical procedure to measure piroxicam consistently were assessed using failure mode and effect analysis. The critical analytical attributes measured were colour (L* lightness, b* yellow to blue colour parameters—in-process critical quality attributes) that are linked to the ability to measure the API content and transmittance. The method validation was based on the accuracy profile strategy and ICH Q2(R1) validation criteria. The accuracy profile obtained with two validation sets showed that the 95% β-expectation tolerance limits for all piroxicam concentration levels analysed were within the combined trueness and precision acceptance limits set at ±5%. The method robustness was tested by evaluating the effects of screw speed (150–250 rpm) and feed rate (5–9 g/min) on piroxicam content around 15% w/w. In-line UV-Vis spectroscopy was shown to be a robust and practical PAT tool for monitoring the piroxicam content, a critical quality attribute in a pharmaceutical HME process.
- 12 February 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (2) , 150
Open AccessDevelopment and Validation of an in-line API Quantification Method Using AQbD Principles Based on UV-Vis Spectroscopy to Monitor and Optimise Continuous Hot Melt Extrusion Process
A key principle of developing a new medicine is that quality should be built in, with a thorough understanding of the product and the manufacturing process supported by appropriate process controls. Quality by design principles that have been established for the development of drug products/substances can equally be applied to the development of analytical procedures. This paper presents the development and validation of a quantitative method to predict the concentration of piroxicam in Kollidon® VA 64 during hot melt extrusion using analytical quality by design principles. An analytical target profile was established for the piroxicam content and a novel in-line analytical procedure was developed using predictive models based on UV-Vis absorbance spectra collected during hot melt extrusion. Risks that impact the ability of the analytical procedure to measure piroxicam consistently were assessed using failure mode and effect analysis. The critical analytical attributes measured were colour (L* lightness, b* yellow to blue colour parameters—in-process critical quality attributes) that are linked to the ability to measure the API content and transmittance. The method validation was based on the accuracy profile strategy and ICH Q2(R1) validation criteria. The accuracy profile obtained with two validation sets showed that the 95% β-expectation tolerance limits for all piroxicam concentration levels analysed were within the combined trueness and precision acceptance limits set at ±5%. The method robustness was tested by evaluating the effects of screw speed (150–250 rpm) and feed rate (5–9 g/min) on piroxicam content around 15% w/w. In-line UV-Vis spectroscopy was shown to be a robust and practical PAT tool for monitoring the piroxicam content, a critical quality attribute in a pharmaceutical HME process.
- 11 March 2019
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 14 (2) , 185
Author Correction: Enhanced Approaches to the Identification, Evaluation, and Control of Impurities
- 11 March 2019
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 14 (2) , 185
Author Correction: Enhanced Approaches to the Identification, Evaluation, and Control of Impurities
- 9 January 2019
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 91 (4) , 2577-2585
Using the Analytical Target Profile to Drive the Analytical Method Lifecycle
Quality by design (ICH-Topic Q8) requires a prospective summary of the desired quality characteristics of a drug product. This is known as the Quality Target Product Profile (QTPP) which forms the basis for the design and development of the product. An analogous term has been established for analytical procedures called the Analytical Target Profile (ATP). The ATP, in a similar fashion to the QTPP, prospectively summarises the requirements associated with a measurement on a quality attribute which needs to be met by an analytical procedure. Criteria defined in the ATP relate to the maximum uncertainty associated with the reportable result that is required to maintain acceptable confidence in the quality decision made from the result. The ATP is used to assess the fitness of an analytical procedure in the development phase and during all changes across the analytical lifecycle. One or more analytical procedures can meet the requirements of an ATP. The ATP can be applied to any quality attribute across any pharmaceutical modality where an analytical procedure is used to generate a reportable result and this paper provides examples from three of these modalities: Small molecules, oligonucleotides and vaccines. Some key performance characteristics will be discussed for each ATP, namely specificity, accuracy and precision, taking into account the expected range of the analyte. The combination of accuracy and precision into a combined uncertainty characteristic will also be discussed as a more holistic approach. The use of the ATP concept will help focus attention on the properties of a method which impact quality decisions rather than method descriptions, and may enable greater regulatory flexibility across the lifecycle using established conditions based on method performance criteria as proposed in the Step 2 version of ICHQ12. The planned revision of ICHQ2 and development of a new guideline: ICHQ14 Analytical Procedure Development will provide a golden opportunity to harmonise the definition of new QbD concepts such as the ATP.
- 9 January 2019
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 91 (4) , 2577-2585
Using the Analytical Target Profile to Drive the Analytical Method Lifecycle
Quality by design (ICH-Topic Q8) requires a prospective summary of the desired quality characteristics of a drug product. This is known as the Quality Target Product Profile (QTPP) which forms the basis for the design and development of the product. An analogous term has been established for analytical procedures called the Analytical Target Profile (ATP). The ATP, in a similar fashion to the QTPP, prospectively summarises the requirements associated with a measurement on a quality attribute which needs to be met by an analytical procedure. Criteria defined in the ATP relate to the maximum uncertainty associated with the reportable result that is required to maintain acceptable confidence in the quality decision made from the result. The ATP is used to assess the fitness of an analytical procedure in the development phase and during all changes across the analytical lifecycle. One or more analytical procedures can meet the requirements of an ATP. The ATP can be applied to any quality attribute across any pharmaceutical modality where an analytical procedure is used to generate a reportable result and this paper provides examples from three of these modalities: Small molecules, oligonucleotides and vaccines. Some key performance characteristics will be discussed for each ATP, namely specificity, accuracy and precision, taking into account the expected range of the analyte. The combination of accuracy and precision into a combined uncertainty characteristic will also be discussed as a more holistic approach. The use of the ATP concept will help focus attention on the properties of a method which impact quality decisions rather than method descriptions, and may enable greater regulatory flexibility across the lifecycle using established conditions based on method performance criteria as proposed in the Step 2 version of ICHQ12. The planned revision of ICHQ2 and development of a new guideline: ICHQ14 Analytical Procedure Development will provide a golden opportunity to harmonise the definition of new QbD concepts such as the ATP.
- 14 December 2018
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 14 (2) , 176-184
Enhanced Approaches to the Identification, Evaluation, and Control of Impurities
- 14 December 2018
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 14 (2) , 176-184
Enhanced Approaches to the Identification, Evaluation, and Control of Impurities
- 26 November 2018
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 22 (12) , 1712-1715
Regulatory Highlights
- 26 November 2018
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 22 (12) , 1712-1715
Regulatory Highlights
- 6 August 2018
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 13 (4) , 367-372
The Delivery of Flexibility from the Application of QbD to API Development
- 6 August 2018
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 13 (4) , 367-372
The Delivery of Flexibility from the Application of QbD to API Development